错配修复蛋白、p53在结直肠癌患者中的表达及临床意义

doi:10.3969/j.issn.1671-7171.2025.10.021

Abstract
Figure/Table
References (0)
Related Citation (15)

Download: PDF (1205 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract 【Objective】To investigate the expression of mismatch repair proteins (MMRP) and p53 in patients with colorectal cancer and their clinicopathological significance.【Methods】 Ninety-eight patients with colorectal cancer were included. According to the presence or absence of MMRP expression, they were divided into the dMMR group (n=20) and the pMMR group (n=78). According to p53 expression, they were divided into the p53-positive group (n=72) and the p53-negative group (n=26). General clinical data were compared between groups, and Spearman correlation analysis was performed to evaluate the relationships among MLH1, PMS2, MSH2, and MSH6 within the MMRP family.【Results】 Tumor diameter was larger in the pMMR group than in the dMMR group. The proportions of high differentiation, TNM stage Ⅲ~Ⅳ, intravascular tumor thrombus, and lymph node metastasis were higher in the pMMR group compared with the dMMR group, with statistically significant differences (P<0.05). In the p53-positive group, the proportions of male patients and TNM stage Ⅰ~Ⅱ were higher than those in the p53-negative group (P<0.05). Among the 20 patients in the dMMR group, MLH1 loss was observed in 6 cases, PMS2 in 7 cases, MSH2 in 3 cases, and MSH6 in 2 cases; MLH1 combined with PMS2 loss was found in 1 case, and MSH2 combined with MSH6 loss was shown in 1 case. MLH1 was significantly positively correlated with PMS2, and MSH2 with MSH6 (both P<0.05).【Conclusion】 Loss of MMRP expression is significantly associated with clinicopathological features such as tumor diameter and degree of differentiation in colorectal cancer patients. p53 positivity is significantly associated with patient gender and TNM stage.

Key words： Colorectal Neoplasms DNA Mismatch Repair Proteins

Received: 26 December 2024

PACS:

R735.35

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	CHEN Haiyan
	MA Haiming
	YUAN Sufang

Cite this article:

CHEN Haiyan,MA Haiming,YUAN Sufang. Expression and Clinicopathological Significance of Mismatch Repair Proteins and p53 in Patients with Colorectal Cancer[J]. JOURNAL OF CLINICAL RESEARCH, 2025, 42(10): 1753-1755.

URL:

http://journal07.magtech.org.cn/yxlcyj/EN/10.3969/j.issn.1671-7171.2025.10.021 OR http://journal07.magtech.org.cn/yxlcyj/EN/Y2025/V42/I10/1753

[1] BILLER L H, SCHRAG D. Diagnosis and treatment of metastatic colorectal cancer: a review[J].JAMA,2021, 325(7): 669-685.
[2] 方邦伟,韦煜,潘剑,等. 855例前列腺癌患者错配修复基因胚系突变临床研究[J].浙江大学学报(医学版),2023,52(2):133-138.
[3] 钟丽,刘茜茜,曲颜丽. 错配修复蛋白在左、右半结肠癌组织中的表达差异及其临床意义[J].现代肿瘤医学,2023,31(1):126-129.
[4] 周兰妮,欧阳富盛,郭保亮,等. 细胞外体积分数联合临床指标构建的列线图预测结直肠癌p53表达[J].临床放射学杂志,2024,43(5):776-782.
[5] 吴亭,张云芳,邱晓堂,等. 滋肾固髓汤通过调控p38MAPK/p53信号通路诱导结直肠癌HCT-116细胞凋亡[J].现代肿瘤医学,2023,31(9):1608-1613.
[6] 中华人民共和国国家卫生健康委员会医政医管局,中华医学会肿瘤学分会. 中国结直肠癌诊疗规范(2020年版)[J].中国实用外科杂志,2020,40(6):601-625.
[7] SCHMITT M, GRETEN F R. The inflammatory pathogenesis of colorectal cancer[J].Nature Rev Immunol,2021, 21(10): 653-667.
[8] 高立香,刘莉,陈颖,等. 错配修复蛋白在乳腺癌中的表达及意义[J].诊断病理学杂志,2023,30(8):779-782.
[9] 丁剑锋,刘颖,靳钦,等. 结直肠癌中DRP1、p53及Ki67的表达及临床意义[J].重庆医学,2023,52(9):1363-1367.
[10] 王春华,王苏杭,许建秋,等. 非小细胞肺癌组织中DNA错配修复蛋白的表达及与临床病理特征的关系[J].浙江医学,2023,45(24):2642-2646.
[11] 罗含欢,霍真,边巴扎西,等. 西藏地区手术切除结直肠癌病理类型及错配修复蛋白、人表皮生长因子受体2、Pan-TRK表达和Eostein-Barr病毒感染情况分析[J].中国医学科学院学报,2023,45(3):422-428.
[12] 仲虎,陈彦,叶松,等. 老年散发性结直肠癌患者错配修复蛋白表达的临床病理特征及预后研究[J].临床消化病杂志,2023,35(1):30-33.
[13] 常守凤,党雅梅,张晓玲,等. 结直肠癌组织的PD-L1水平和P53突变情况及临床意义分析[J].临床肿瘤学杂志,2022,27(12):1119-1123.
[14] 包翔,朱倩影,汤汇涓,等. 灵芝酸D通过调控p53/Bax通路对人结直肠肿瘤细胞的作用机制研究[J].中国临床药理学杂志,2022,38(12):1339-1343.
[15] 高超,郑晨,黄新,等. 同源盒A10和P53蛋白在结直肠癌中的表达及其临床意义[J].中华普通外科学文献,2023,17(1):40-44.